Last reviewed · How we verify
Anakinra (r-metHuIL-1ra)
Anakinra (r-metHuIL-1ra) is a IL-1 receptor antagonist Small molecule drug developed by Amgen. It is currently FDA-approved for Rheumatoid arthritis, Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes), Gout.
Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.
Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation. Used for Rheumatoid arthritis, Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes), Gout.
At a glance
| Generic name | Anakinra (r-metHuIL-1ra) |
|---|---|
| Sponsor | Amgen |
| Drug class | IL-1 receptor antagonist |
| Target | IL-1 receptor type I (IL-1RI) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Anakinra competitively inhibits interleukin-1 (IL-1) by binding to the IL-1 receptor type I, preventing both IL-1α and IL-1β from activating downstream inflammatory pathways. This blocks the production of pro-inflammatory mediators and reduces systemic inflammation. It is used primarily in autoinflammatory and autoimmune conditions where IL-1 plays a central pathogenic role.
Approved indications
- Rheumatoid arthritis
- Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes)
- Gout
Common side effects
- Injection site reactions
- Infections
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes (PHASE2)
- Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome (PHASE2)
- Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) (PHASE4)
- The SPECTRA Study (PHASE2)
- Juvenile Rheumatoid Arthritis (PHASE2)
- Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anakinra (r-metHuIL-1ra) CI brief — competitive landscape report
- Anakinra (r-metHuIL-1ra) updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Anakinra (r-metHuIL-1ra)
What is Anakinra (r-metHuIL-1ra)?
How does Anakinra (r-metHuIL-1ra) work?
What is Anakinra (r-metHuIL-1ra) used for?
Who makes Anakinra (r-metHuIL-1ra)?
What drug class is Anakinra (r-metHuIL-1ra) in?
What development phase is Anakinra (r-metHuIL-1ra) in?
What are the side effects of Anakinra (r-metHuIL-1ra)?
What does Anakinra (r-metHuIL-1ra) target?
Related
- Drug class: All IL-1 receptor antagonist drugs
- Target: All drugs targeting IL-1 receptor type I (IL-1RI)
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Autoinflammatory syndromes (e.g., cryopyrin-associated periodic syndromes)
- Indication: Drugs for Gout
- Compare: Anakinra (r-metHuIL-1ra) vs similar drugs
- Pricing: Anakinra (r-metHuIL-1ra) cost, discount & access